All In Biotech

Drug Trial Radar · NCT04005690

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

A Window of Opportunity Strategy for Targeted Pathway Inhibition in Patients With Pancreatic Ductal Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Aug 1, 2019

Primary completion

Jun 1, 2027

Study completion Feb 1, 2028

Sponsor

Lead sponsor
OHSU Knight Cancer InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
American Association for Cancer Research; Oregon Health and Science University; Genentech, Inc.; Cardiff Oncology
First posted
Jul 2, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This early phase I trial aims to determine how cobimetinib, olaparib, onvansertib, azenosertib, AZD5305 or tremelimumab works in patients with pancreatic cancer. Validation of cobimetinib, olaparib, onvansertib azenosertib, AZD5305 and tremelimumab molecular targets will be explored by comparing pre-treatment biopsies with post-treatment specimens. This knowledge will help design future biomarker driven trials to determine whether giving cobimetinib, or olaparib, or onvansertib or azenosertib, or AZD5305, or tremelimumab will work better than standard treatments in patients with pancreatic cancer.

Conditions

  • Locally Advanced Pancreatic Ductal Adenocarcinoma
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • Stage II Pancreatic Cancer AJCC v8
  • Stage III Pancreatic Cancer AJCC v8
  • Stage IV Pancreatic Cancer AJCC v8
  • Unresectable Pancreatic Ductal Adenocarcinoma
  • Borderline Resectable Pancreatic Ductal Adenocarcinoma
  • Resectable Pancreatic Ductal Adenocarcinoma

Interventions

  • CobimetinibDrug

    Given PO

  • OlaparibDrug

    Given PO

  • OnvansertibDrug

    Given PO

  • AzenosertibDrug

    Given PO

  • SaruparibDrug

    Given PO

  • TremelimumabBiological

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of all pharmacodynamic feasibility-evaluable participants within a study arm that have a measurable change in post-treatment tumor biology from baselineTime frame: Changes in tumor biology from baseline (i.e., Day 0) and on-treatment biopsy (i.e., 10 days from start of study intervention)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • OHSU Knight Cancer Institute

    Portland, Oregon · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.